Lineage Cell Therapeutics, Inc. reports material agreement in SEC 8-K

Lineage Cell Therapeutics, Inc. filed an 8-K covering a material definitive agreement, an acquisition or disposition of assets, results of operations or financial condition, and an unregistered sale of equity securities. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.